PMID- 38423814
OWN - NLM
STAT- MEDLINE
DCOM- 20240318
LR  - 20240318
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 42
IP  - 8
DP  - 2024 Mar 19
TI  - Co-administration of the adjuvanted recombinant zoster vaccine with other adult 
      vaccines: An overview.
PG  - 2026-2035
LID - S0264-410X(24)00194-4 [pii]
LID - 10.1016/j.vaccine.2024.02.035 [doi]
AB  - BACKGROUND: The adjuvanted recombinant zoster vaccine (RZV; Shingrix(R), GSK) is a 
      subunit vaccine that has been approved for the prevention of herpes zoster in 
      adults. Co-administration of two vaccines in a single visit is a strategy to 
      improve overall vaccine coverage. OBJECTIVES: This review aims to consolidate 
      available clinical data on RZV co-administration, providing an overview of 
      safety, reactogenicity and immunogenicity. METHODS: RZV co-administration data 
      were obtained from five randomised, open-label, phase III clinical trials with 
      similar study designs. The co-administered vaccines included: quadrivalent 
      seasonal inactivated influenza vaccine (IIV4; NCT01954251), 23-valent 
      pneumococcal polysaccharide vaccine (PPSV23; NCT02045836), 
      reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine (Tdap; 
      NCT02052596), 13-valent pneumococcal conjugate vaccine (PCV13; NCT03439657) and 
      COVID-19 mRNA-1273 booster (NCT05047770). Eligible participants were healthy 
      adults aged >/=50 years. RESULTS: A total of 3,974 participants were vaccinated 
      (co-administration: 1,973; sequential: 2,001) across the five trials. Vaccine 
      response rates to RZV were similar for co-administration (range: 95.8-99.1 %) and 
      sequential groups (range: 95.1-99.1 %). Immune responses to RZV and the other 
      vaccines (with the exception of pertactin) were non-inferior when the vaccines 
      were co-administered compared with sequentially administered. Overall incidences 
      of solicited local and general adverse events (AEs), unsolicited AEs, serious AEs 
      or potential immune-mediated diseases were similar after co-administration or 
      sequential administration. Myalgia was the most common solicited systemic AE 
      (co-administration: 38-64 %; sequential: 30-59 %). Shivering and fever were more 
      common after co-administration (16 % and 21 %, respectively) than after 
      sequential administration (both 7 %) of RZV and PPSV23. CONCLUSIONS: 
      Co-administration of RZV with routine vaccines does not significantly alter the 
      reactogenicity, immunogenicity or safety of RZV or the co-administered vaccine. 
      Healthcare practitioners should consider routine co-administration of RZV with 
      other adult vaccines to improve vaccination coverage.
CI  - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Omar Ali, S
AU  - Omar Ali S
AD  - GSK, 14200 Shady Grove Rd, Rockville, MD, USA. Electronic address: 
      omar.o.ali@gsk.com.
FAU - Dessart, Christophe
AU  - Dessart C
AD  - GSK, Avenue Fleming 20, 1300 Wavre, Belgium. Electronic address: 
      christophe.d.dessart@gsk.com.
FAU - Parikh, Raunak
AU  - Parikh R
AD  - GSK, Avenue Fleming 20, 1300 Wavre, Belgium.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240228
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Herpes Zoster Vaccine)
RN  - 0 (Diphtheria-Tetanus-acellular Pertussis Vaccines)
RN  - 0 (Vaccines, Synthetic)
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Vaccines, Combined)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Herpes Zoster Vaccine
MH  - *Herpes Zoster/prevention & control
MH  - *Diphtheria-Tetanus-acellular Pertussis Vaccines
MH  - Vaccines, Synthetic/adverse effects
MH  - Adjuvants, Immunologic
MH  - Vaccines, Combined
MH  - Immunogenicity, Vaccine
COIS- Declaration of competing interest All authors are employees of GSK and hold or 
      may hold stock options.
EDAT- 2024/03/01 01:27
MHDA- 2024/03/18 06:42
CRDT- 2024/02/29 21:53
PHST- 2023/10/10 00:00 [received]
PHST- 2024/02/05 00:00 [revised]
PHST- 2024/02/10 00:00 [accepted]
PHST- 2024/03/18 06:42 [medline]
PHST- 2024/03/01 01:27 [pubmed]
PHST- 2024/02/29 21:53 [entrez]
AID - S0264-410X(24)00194-4 [pii]
AID - 10.1016/j.vaccine.2024.02.035 [doi]
PST - ppublish
SO  - Vaccine. 2024 Mar 19;42(8):2026-2035. doi: 10.1016/j.vaccine.2024.02.035. Epub 
      2024 Feb 28.